Michael Rodio | Sept. 3, 2013 | Harper Cancer Research Institute
Epithelial ovarian cancer is a grim diagnosis. Because more than 75 percent of women with ovarian cancer have metastatic disease when they are diagnosed, survival rates have not improved for three decades. And unlike breast cancer or prostate cancer, ovarian cancer is not widely studied: Researchers have only recently started to understand how it works on the molecular level, and its origin site in the body is still a mystery.
“The Midwest has a tremendous concentration of basic and clinical ovarian cancer researchers, so we wanted to provide an opportunity to gather here at Harper to discuss our individual strengths and resources, with the goal of establishing new collaborations that will ultimately help women with ovarian cancer” said Sharon Stack, the Ann F. Dunne and Elizabeth Riley Director of the Harper Cancer Research Institute and professor of chemistry and biochemistry.
Recognizing this collection of talent, Dr. Stack sought to get the best minds in ovarian cancer research under one roof.
The result was the inaugural Indiana-Illinois End Epithelial Ovarian Cancer Coalition Workshop (IIEEOCC), which brought nearly 40 leading cancer researchers to the Harper Cancer Research Institute on June 10 and 11, 2012.